Clinical practice of sublingual immunotherapy in the U.S. dates back more than 100 years with recent research validating what has been observed clinically for decades.
- Bibliography — modern research references for sublingual immunotherapy, including findings through the Cochrane Collaboration, World Health Organization, and Agency for Healthcare Research & Quality (AHRQ).
- COVID-19 Research — Throughout the last year, sublingual immunotherapy has been amplified as a safe way to continue allergy treatment while remaining socially distant and freeing up space in practices for more urgent needs. Now, there’s research to back it.
- Supporting Evidence — studies that specifically address the key tenets of the La Crosse Method™ Protocol
- La Crosse Method Protocol Author Research
A large number of controlled clinical trials in Europe have shown the effectiveness of sublingual immunotherapy in the treatment of allergic rhinitis and asthma for single antigens. More studies are underway in the U.S. and globally, including studies that explore food allergies. Additional research has shed light on the mechanisms behind sublingual immunotherapy, notably the unique role dendritic cells under the tongue play in building allergen tolerance.